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Abstract: Several epidemiological and animal studies have suggested that polyphenols, a group of secondary plant metabolites occurring 
mainly in the plant kingdom, may have a protective effect against some chronic degenerative diseases such as cancer. Polyphenols are 
part of the human diet, being present in vegetal food and beverages. Among them, an olive biophenol named hydroxytyrosol [2-(3,4-
dihydroxyphenyl)ethanol, HTyr] has recently received particular attention because of its antioxidant, antiproliferative, pro-apoptotic, and 
anti-inflammatory activities, which have the potential to specifically counteract all cancer hallmarks, thus representing the expectant bio-
logical activities underlying the anti-tumor properties of this polyphenol. After a description of the synthetic procedures to prepare pure 
HTyr, this review takes into consideration the chemopreventive and chemotherapeutic potential of HTyr as the result of its antioxidant, 
antiproliferative and anti-inflammatory activities. In particular, the review is focused on the current knowledge of the main cellular and 
molecular mechanisms used by HTyr to affect carcinogenesis, highlighting the specific oncogenic and inflammatory signaling pathways 
potentially targeted by HTyr. 
Keywords: Hydroxytyrosol, polyphenols, olive mill, olive oil wastewaters, synthesis, oxidation, proliferation, inflammation, signaling, can-
cer, carcinogenesis, anti-cancer activity. 
1. INTRODUCTION 
Hydroxytyrosol [2-(3,4-dihydroxyphenyl)ethanol, HTyr] is a 
natural compound firstly recognized by Stoll et al. as a component 
of echinacoside, a phenolic glycoside showing antibiotic activity 
against Staphylococcus aureus extracted from the roots of Echina-
cea angustifolia [1]. As a matter of fact, echinacoside contains one 
glucose and two rhamnose moieties, glycosidically linked to one 
caffeic acid and one dihydroxyphenylethanol residue at the cen-
trally situated rhamnose Fig. (1).
In 1966, Panizzi et al. isolated oleuropein, a bitter glucoside of 
the olives exhibiting hypotensive activity, and firstly clarified its 
chemical structure [2]. In the presence of -glucosidase, oleuropein 
was hydrolyzed producing an aglycone and glucose. The chemical 
structure of the aglycone (HTyr) was demonstrated by the forma-
tion of some crystalline derivatives such as tri(p-nitrobenzoate) and 
dimethyl ether.
Several papers reported the chemical composition of olive fruits 
(Olea europea L.) and virgin olive oils in terms of polyunsaturated 
fatty acids and phenolic compounds [3]. These molecules are re-
sponsible for the human beneficial properties of virgin olive oil, 
making it unique from the nutritional point of view. Among bio-
phenols, one of the most interesting is HTyr that has been 
widely studied demonstrating its numerous biological proper-
ties. This small molecule is a potent inhibitor of copper sulfate-
induced LDL oxidation and of platelet aggregation (potentially 
reducing the risk of coronary heart disease and atherosclerosis) [4], 
acts as antioxidant and metal chelator in animal models [5], scav-
enges superoxide anion (O2.- ) generated by either human polymor-
phonuclear cells or the xanthine/xanthine oxidase system [6], inhib-
its proliferation and induces apoptosis in HL-60 leukemia cells [7], 
prevents DNA damage and tyrosine nitration induced by peroxyni-
trite [8], protects toward hydrogen-peroxide (H2O2)-induced dam-
age in human erythrocytes [9], inhibits passive smoking-induced 
*Address correspondence to these authors at the Università degli Studi della Tuscia, 
Dipartimento di Scienze e Tecnologie per l’Agricoltura, le Foreste, la Natura e 
l’Energia (DAFNE), Via S. Camillo De Lellis, 01100 Viterbo, Italy; Tel: +39 761 
357452; Fax: +39 761 357242; E-mail: berninir@unitus.it; and Università degli Studi 
della Tuscia, Dipartimento di Scienze Ecologiche e Biologiche (DEB), Largo 
dell’Università, 01100 Viterbo, Italy; Tel: +39 761 357035; Fax: +39 761 357751;  
E-mail: velotti@unitus.it.
OH
HO
Hydroxytyrosol (HTyr)
O O
OH
HO
HO
OH
O
O
O
HO
HO
OHO
O
OHHO
HO
Me
O OH
OH
Echinacoside
HO
O
HO
Oleuropein
O
HO
O
O
MeO O
O
HO
HO
OH
OH
Fig. (1). Chemical structure of hydroxytyrosol (HTyr), echinacoside and 
oleuropein. 
oxidative stress [10], exhibits anti-inflammatory activity [11], ex-
erts anti-microbial and anti-mycoplasmal activity [12].
Considering the health-promoting biological properties of 
HTyr, many efforts have been made to obtain extracts containing 
HTyr from natural sources, allowing thus its potential use as a die-
tary supplement. As a matter of fact, olive pulp extracts were ob-
tained through patented extraction procedures from selected varie-
ties of olives. At the same time, several procedures have been de-
scribed for the recovery of polyphenols and HTyr from olive oil 
processing by-products. The definitive production of olive oil is 
carried out by a three-phase extraction system, which generates 
liquid and solid wastes. The liquid waste, named olive mill waste-
waters (OMWW), contains a mixture of water and oil from the 
olive vegetal matter, with additional water added from processing. 
The solid waste is a combination of olive pulp and stones. The use 
of a more modern two-phases olive oil processing technique, in 
which no water is added, generates only a byproduct, named alpe-
rujo, that is a combination of liquid and solid waste. This system 
involves a reduction of OMWW volume with an increased concen-
tration in organic matter [13]. Most frequently, OMWW are dis-
charged into evaporation ponds or directly dumped in rivers or 
spread on soil. These disposals create a number of environmental 
and ecological problems in all olive-producing countries of the 
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Mediterranean region. Olive oil by-products have a high polluting 
organic load and phenolic compounds are the major contributors to 
their toxicity and antimicrobial activity [14]. The partition coeffi-
cient (oil/water) of most olive biophenols, ranging from 6x10-4 to 
1.5, is in favor of the water phase. Then, the olive fruits are very 
rich in phenolic compounds, but only 2% of the total phenolic con-
tent of the olive fruit passes in the oil phase, while the remaining 
amount is lost in the OMWW and in the pomace (approximately 
53% and 45%, respectively) [15]. On the other hand, phenolic com-
pounds are high value added compounds. Then, procedures for the 
selective extraction of these compounds allow the detoxification of 
OMWW and, at the same time, the recovery of biologically active 
compounds of interest in cosmetic, pharmaceutical and food indus-
tries. A recent review described the most recent patents developed 
to improve procedures for recovering phenolic compounds from 
olive oil, olive oil industrial by-products and OMWW [16]. Among 
them, membrane technologies are very efficient for producing puri-
fied fractions as powder or concentrated solutions of biologically 
active phenolic compounds for industrial applications [17]. For 
example, Olea fractions are obtained from olive oil by-products 
such as pomace by an innovative process of separation, based on 
membrane technologies defined as BAT (Best Available Technol-
ogy) and recognized from EPA (Environmental Protection Agency) 
[17d, 17e]. HPLC/DAD/MS analysis of these fractions showed that 
they contain 90% of hydroxytyrosol and derivatives. These innova-
tive technologies are recently utilized also for other vegetal matri-
ces such as sweet chestnut (Castanea sativa M.) and artichoke leafs 
(Cynara), to obtain fractions enriched in hydrolysable tannins [18] 
and hydroxycinnamic derivatives [19], respectively.  
Until some years ago, pure HTyr was commercially available 
only at a high price (more than 1000 $ per gram). Currently, HTyr 
is commercialized by many chemical companies at a lower cost, 
because in recent times several synthetic procedures have been 
optimized.  
This review article is focused on both the synthetic procedures 
for HTyr production and the anti-cancer potential of HTyr. In par-
ticular, after a survey of HTyr synthesis, the current knowledge of 
the main cellular and molecular mechanisms used by HTyr to affect 
carcinogenesis is discussed, highlighting the specific oncogenic and 
inflammatory signaling pathways potentially targeted by this com-
pound.  
2. SYNTHETIC PROCEDURES 
In 1949, Schöpf et al. claimed the first synthesis of HTyr; a 
crystalline compound (m.p. 81-83 °C) was isolated according to the 
three-steps procedure described in (Scheme 1) [20]. 2-(3,4-Di 
methoxyphenyl)ethanol 1 was demethylated by 48% aqueous hy-
drobromic acid to produce the corresponding bromide 2, that was 
converted into the triacetoxy derivative 3 and then hydrolyzed by 
methanolic NH3 to give a compound identified as HTyr. Some 
years ago, in order to evaluate the bacteriostatic action of HTyr on 
Escherichia coli B., Khafagy and Lambooy prepared a compound 
by using a new synthetic approach based on the direct demethyla-
tion of 2-(3,4-dimethoxyphenyl)ethanol 1 by anhydrous AlCl3 in a 
benzene solution [21]. According to the previously reported value, 
this compound showed m.p. between 82 and 84 °C [20].  
In 1983, Baraldi et al. repeated the above-described procedures 
and, although the authors obtained two different compounds show-
ing the previously reported melting points [22], the IR and the 1H
NMR data were not consistent with the structure of HTyr; HTyr 
was only the minor product of the reaction (less than 10% yield). 
Then, the same authors synthesized pure HTyr by a new procedure 
starting from commercially available 3,4-dimethoxyphenylacetic 
acid 4 (Scheme 2). After a demethylation by hydriodic acid in the 
presence of red phosphorus, the corresponding dihydroxy derivative 
5 was reduced in boiling THF solution with an excess of LiAlH4 to 
give HTyr in 66% yield. The physical and spectroscopic data of this 
compound were consistent with the expected structure of HTyr, as 
reported by Panizzi et al. [2].  
The reduction of 3,4-dihydroxyphenylacetic acid 5 using 
LiAlH4 was optimized in dry THF (obtaining HTyr in 82.8% yield) 
by Capasso and co-workers in 1999. After chromatographic purifi-
cation on a silica gel column, pure HTyr was obtained in 79% yield 
and it was fully characterized by 1H NMR, 13C NMR, UV spectros-
copy and EIMS spectrometry [23].  
One year later, Tuck et al. described the reduction of 3,4-
dihydroxyphenylacetic acid 5 by previously prepared tetrabuty-
lammonium boronate. Under these experimental conditions, HTyr 
was isolated as  pale yellow oil in quantitative yields [24].  
Esters have been used as alternative starting materials for the 
preparation of HTyr. In 1988, Bianco and co-workers described an 
improved reduction of 3,4-dihydroxyphenethyl acetate 6 using 
NaBH4 in water (obtaining HTyr in 80% yield) [25]. The authors 
supposed that the reaction involved the loss of hydride forming 
sodium alkoxyborohydrides capable of reducing esters.  
Ten years later, 3,4-dihydroxyphenylacetic acid 5 was methy-
lated using TMSCHN2 to produce the corresponding methyl ester 7,
which was reduced by NaBH4 in ice water affording to HTyr in 
98% yield (Scheme 4) [26]. 
Other starting materials for the synthesis of HTyr included tyro-
sol 8, homovanillyl alcohol 9, 3,4-dimethoxybenzaldehyde 10 and 
its demethylated derivative 11, oleuropein 12.
Both enzymatic and chemical procedures have been optimized 
for the oxidative conversion of commercially available tyrosol 8
into HTyr. Tyrosinase (EC 1.14.18.1) is a polyphenol oxidase ex-
hibiting both monophenolase and diphenolase activity. Firstly, it 
catalyzes the hydroxylation of monophenols to o-phenols and then 
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Scheme 1. Synthesis of HTyr proposed by Schöpf et al. [20]. 
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the oxidation of o-phenols to the corresponding o-quinones. These 
compounds are very reactive and produced non-enzymatically 
brown pigments. However, under reducing conditions, o-quinones 
are reduced to the o-diphenol precursors. This strategy was used by 
Espin et al. for the synthesis of HTyr (Scheme 5) [27]. Mushroom 
tyrosinase was used in the presence of excessive ascorbic acid; the 
reaction occurred in an aqueous medium, at neutral pH, at room 
temperature. Once the desired concentration of HTyr was obtained, 
it was filtered; the enzyme was retained in the filter and reused 
again. Using a similar strategy, HTyr was synthesized from tyrosol 
using Agaricus bisporous tyrosinase immobilized on commercial 
available epoxy-resin Eupergit® C250L and coated by the Layer-
by-Layer method (LbL) [28].  
A convenient bioconversion of tyrosol 8 into HTyr was suc-
cessfully performed using a soil bacterium, Serratia marcescens
strain, under environmental friendly conditions [29]. As an alterna-
tive, a whole cell system, such as Pseudomonas aeruginosa immo-
bilized resting cells in calcium alginate beads, converted tyrosol 8
into HTyr in 86% yield. The use of immobilized cells in repeated 
batches demonstrated noteworthy activity stabilization, since the 
biocatalyst was reused for at least four batches with loss of effi-
ciency [30].  
2-Iodoxybenzoic acid (IBX) [31], its stabilized (non explosive) 
formulation (SIBX) [32] and polymer-supported version such as 
IBX-polystyrene [33] Fig. (2) are reagents that mimic the mono-
phenolase activity of tyrosinase to produce o-quinones from phe-
nols. The following in situ reduction produced the corresponding 
catecholic derivatives. A wide number of examples of o-
hydroxylation of phenolic compounds and oxidative demethylation 
of 2-methoxyphenols for the synthesis of biologically and industri-
ally relevant catechols are described in a recent review [34]. Spe-
cifically, the (S)IBX-mediated oxidation of tyrosol 8 and homova-
nillyl alcohol 9 followed by an in situ sodium dithionite reduction 
produced HTyr in modest yields [35, 36] (Scheme 7, Table 1, en-
tries 1,3). The efficiency and eco-friendly character of IBX-
polystyrene (Table 1, entries 2,4) to give HTyr are noteworthy. As a 
matter of fact, at the end of the reaction, the solution containing 
HTyr was filtered; IBX-polystyrene was recovered, regenerated and 
reused for at least ten subsequent runs. No side-chain oxidation 
product was observed, demonstrating that recycled IBX-polystyrene 
fully conserved its high regio- and chemo-selectivity [37].  
Alternatively, HTyr was prepared from tyrosol 8 and homova-
nillyl alcohol 9 using IBX by an indirect route [38]. Firstly, the 
protection of the primary alcohol function of compounds 8 and 9
was performed using dimethyl carbonate (DMC), an ecofriendly 
chemical, in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) or sulfuric acid as catalyst. This allowed to obtain the corre-
sponding methyl carbonates 13 and 14 in quantitative yields. Their 
subsequent IBX-oxidation and reduction furnished hydroxytyrosol 
methyl carbonate 15 in 85% yield. Finally, the basic hydrolysis 
gave HTyr in quasi-quantitative yields (Scheme 7). Compound 15
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Table 1. IBX-Mediated Oxidation of Tyrosol 8 and Homovanillyl Alcohol 9 
Entry Starting Material Experimental Conditions HTyr (%)a
1
2
Tyrosol 8
Tyrosol 8
IBX, CH3OH, - 25° C 
IBX-polystyrene, DMC, rt 
30
>98 
3
4
Homovanillyl alcohol 9
Homovanillyl alcohol 9
SIBX, acetone/H2O=9/1, rt 
IBX-polystyrene, DMC, rt 
42
93
a After chromatographic purification. 
was proven to be an excellent starting material for the synthesis of a 
large panel of novel HTyr derivatives [39]. 
A mild photochemical synthesis of HTyr from tyrosol 8 was de-
scribed by Azabou et al. [40]. Tyrosol was converted into HTyr (in 
64 % yield) by hydrogen peroxide oxidation, using aluminum-iron 
pillared clay [(Al-Fe)PILC] catalyst under UV irradiation, at =254 
nm, at room temperature. 
Recently, Bovicelli et al. described an expedient synthesis of 
HTyr from tyrosol 8, but several steps involving monobromination, 
substitution, diacetylation and deprotections were necessary to give 
HTyr in a low overall yield [41]. 
More recently, Zappia et al. reported an efficient and economi-
cal synthesis of HTyr from tyrosol 8 via Baeyer-Villiger oxidation 
(Scheme 9) [42]. The synthesis began with the protection of tyrosol 
8 to give the acetate 20 in quantitative yield; the o-formylation fur-
nished the corresponding salicylaldehyde 21 in 72% yield. This 
compound was then subjected to a Bayer-Villiger oxidation to gen-
erate the catechol moiety. The subsequent hydrolysis gave HTyr in 
79% yield. 
3,4-Dihydroxybenzaldeyde 11 was used as starting material for 
the production of HTyr by Verhe et al. [43]. Compound 11 was 
converted into the corresponding cyanohydrine 23 and then hydro-
lyzed to 3,4-dimethoxyphenyl acetic acid 24. The corresponding 
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methyl ester 25 was demethylated affording to catecholic ester 26
and finally reduced to HTyr (Scheme 10).  
More recently, commercially available 3,4-dihydroxybenzal 
dehyde 12 was used as starting material by Zhang et al. [44]. The 
two free hydroxyl groups of compound 12 were firstly protected by 
the benzyl group. Subsequently, one carbon homologation of the 
protected aldehyde was achieved via the -cyanoenamine 28, then 
converted to the carboxylic acid 29 under acidic conditions. Using 
NaBH4, compound 29 was reduced into the corresponding alcohol. 
HTyr was finally obtained by hydrogenolysis under Pd-C/H2 condi-
tions (Scheme 11).
As reported above, HTyr was obtained by hydrolysis of oleu-
ropein [2]. Gambacorta et al. described an original procedure, based 
on the preventive protection of the catecholic moiety of oleuropein 
into the corresponding acetonide 31 to protect the molecule against 
oxidation, thereby allowing long-term storage. The subsequent 
alkaline hydrolysis of this derivative and deprotection of the aceton-
ide group furnished HTyr in a satisfactory yield (Scheme 12) [45].  
Briante et al. reported an efficient enzymatic hydrolysis of oleu-
ropein to give HTyr, by using homogeneous recombinant -
glycosidase from the hyperthermophilic archeon Sulfolobus solfa-
taricus expressed in Escherichia Coli (EcSgly) immobilized on a 
chitosan support [46]. 
HYDROXYTYROSOL AND CANCER 
As mentioned above, HTyr is one of the major active phenolic 
compounds in virgin olive oils [3]. Epidemiological studies showed 
an inverse correlation between olive oil phenol dietary consumption 
and cancer incidence and number, notably colorectal, breast and 
prostate cancers [47-49]. Animal studies also demonstrated protec-
tion by olive oil phenols towards chemical-induced carcinogenesis, 
UV-induced skin cancer and spontaneous liver tumors. Other ani-
mal studies reported that oleuropein provokes tumor regression [48-
50]. Therefore, epidemiological and experimental evidence suggest
a possible role of olive oil phenols like HTyr in the prevention and 
the treatment of cancer. 
In an important position of a paper published in January 2000, 
Hanahan and Weinberg listed the following six hallmarks of cancer, 
as essential requisites for tumorigenesis: sustained proliferative 
signaling, insensitivity to antigrowth signals, limitless replicative 
potential, evasion of apoptosis, sustained angiogenesis, and tissue 
invasion and metastasization [51]. Moreover, although for a long 
time tumors have been considered as insular masses of proliferating 
cancer cells, in the last decade since the publication of the paper, it 
has become increasingly clear that tumors are complex tissues 
composed of multiple distinct cell types, including transformed and 
non-transformed cells. The non-transformed tumor-associated com-
ponent creates the “tumor microenvironment”, which contributes to 
the acquisition of hallmark traits of tumorigenesis. “Tumor micro-
environment” includes infiltrating immune cells, some of which, as 
some inflammatory cells of the innate immunity, serve to promote 
tumor development. Therefore today, immune inflammatory cells 
and inflammation have been added as the 7th cancer hallmark [52].
Several studies demonstrated that HTyr is a potent antioxidant
phenol and also possesses antiproliferative, pro-apoptotic, as well 
as anti-inflammatory activities [47-50, 53]. These activities have 
the potential to specific counteract cancer hallmarks, representing 
thus the expectant biological activities underlying the anti-tumor
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properties of HTyr. The cellular and molecular mechanisms under-
lying these HTyr-mediated biological activities are not completely 
clear. Indeed, because of the potential chemopreventive and che-
motherapeutic properties of HTyr, investigations devoted to the 
elucidation of HTyr mode and mechanisms of action have gained 
recently increasing interest in cancer research. Another unclear 
point is represented by the reachable plasma concentrations of HTyr 
following HTyr administration. The large difference in plasma 
HTyr concentrations reported in the literature is mostly correlated 
to the difference in the bioavailability of HTyr [54-56]. The admini-
stration of HTyr as olive oil ingestion, that is HTyr associated with 
lipids and other polyphenols, lead to the absorption of approxi-
mately 44% of the total HTyr amount [55]. In contrast, the admini-
stration of HTyr as a purified compound in aqueous solution gave 
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approximately 10% of HTyr absorption [56]. Taking into account 
these considerations, some authors have suggested that physiologi-
cal HTyr concentrations in the plasma could be between 10 and 100 
M [57].  
This part of the review converses the studies involving cellular 
and molecular mechanisms used by HTyr to affect carcinogenesis, 
and highlights the specific signaling pathways potentially targeted 
by HTyr. The knowledge of the molecules directly targeted by 
HTyr relative to both the experimental cell system (normal vs tumor 
cells) and the range of HTyr concentrations is essential for a ra-
tional use of this compound in cancer prevention and treatment. 
4. OXIDATION AND CANCER 
As a consequence of aerobic metabolism, aerobic organisms 
produce a wide range of oxygen radicals and other reactive oxygen 
species (ROS), including free radicals (e.g. O2.- and hydroxyl radi-
cal OH.-) and non-radical compounds (e.g. H2O2). ROS are particu-
larly transient species due to their high chemical reactivity, and, 
because oxidants by nature, they influence the redox intra- and 
extra-cellular status.  
ROS can be generated from both endogenous and exogenous 
sources. Intracellular ROS can be generated by various enzyme 
systems, including the mitochondrial electron transport chain, cyto-
chrome P450 in the endoplasmic reticulum, lipoxygenase, cy-
clooxygenase (COX), the NADPH oxidase complex, xanthine oxi-
dase and peroxisomes [58]. Endogenous ROS can derive from in-
nate immune cells (e.g. neutrophils, eosinophils and macrophages) 
activated by pathogens and/or host factors. Extracellular ROS are 
frequently a consequence of modifications of plasma membrane 
proteins and extracellular environment. The principal exogenous 
sources of ROS are those resulting from exposure to environmental 
agents, including radiations, xenobiotics, barbiturates, and metal 
(redox and non-redox) ions [59, 60]. ROS production is controlled 
by both endogenous enzymatic antioxidant systems like superoxide 
dismutases (Cu/ZnSOD, MnSOD), glutathione (GSH) peroxidase 
and catalase, and non-enzymatic antioxidants like GSH [60]. Fur-
thermore, exogenous compounds mainly arising from foods, like 
vitamins C and E, carotenoids, and polyphenols, also are essential 
for protection from oxidation.  
A persistent imbalance between antioxidants and pro-oxidants 
in favor of the latter results in excessive ROS levels, which lead to 
oxidative stress. Elevated oxidative stress is observed in many solid 
tumors and carcinoma cell lines. Indeed, ROS, reacting with all 
types of cell molecules, including nucleic acids, proteins, lipids, 
carbohydrates and small metabolites, can cause both genotoxic and 
non-genotoxic damages as well as the modulation of numerous cell 
signaling cascades, including those associated to cell proliferation, 
cell death, senescence and inflammatory responses. Generally, low 
oxidative stress may lead to an increased rate of genetic mutations 
and signaling pathways promoting cell proliferation and survival, 
whereas higher oxidative stress levels are more likely to cause tu-
mor cell death and/or senescence [61]. Therefore, ROS play a dual 
role towards tumors, being either beneficial or harmful respectively 
[62]. In particular, ROS-mediated pro-tumorigenic function consists 
in the induction of nondestructive oxidative damage in non-
transformed and transformed cells, as well as the promotion of me-
tastasis [63, 65]. Thus, ROS can play a pivotal role in the initiation 
and the promotion/progression of carcinogenesis [65-67]. Moreo-
ver, oxidative stress plays an essential role in the induction of both 
pro-tumorigenic inflammatory responses and oxidative damage to 
anti-tumor immune cells, further promoting carcinogenesis (see 6. 
Inflammation and cancer). 
ROS-mediated genotoxic damage mostly involves direct 
changes in genomic DNA ultimately lead to gene mutations, while 
non-genotoxic damage includes modulation of gene expression and 
signaling cascades. Both events, occurring in critical cellular proc-
esses, lead to tumor development.  
Concerning ROS-mediated genotoxicity, it is known that DNA 
is a particularly important oxidation target. Indeed, ROS can di-
rectly react with DNA molecules, causing strand breaks and 
pyrimidine and purine lesions, which can affect the integrity of the 
genome and induce permanent genetic alterations [67]. In addition, 
ROS can indirectly cause DNA damage. For example, H2O2 and 
O2.- may initiate DNA damage by interacting with transition metal 
ion chelates, leading to .OH production. In some cases, the genera-
tion of free radicals is closely linked to the involvement of redox-
active metals as iron, and, under stress conditions, O2.- excess 
causes free iron release from iron-containing molecules leading to 
the generation, through the “Fenton reaction”, of highly reactive 
.OH. [60]. This radical is perhaps the most frequent DNA damaging 
species, with over twenty different products derived from its attack 
to DNA bases. Elevated levels of such DNA lesions can induce 
aberrant modifications in adjacent DNA, significantly contributing 
to the genetic instability strongly implicated in all stages of car-
cinogenesis. Moreover, surmounting evidence implicates the in-
volvement of mitochondrial oxidative DNA damage in human car-
cinogenesis, being mitochondrial DNA more susceptible to oxida-
tive damage than nuclear DNA [68]. 
ROS-mediated non-genotoxic damage involves epigenetic al-
terations that can play a key role in carcinogenesis. In fact, ROS 
production can cause alterations in DNA methylation (hypo- or 
hyper- methylation) patterns, altering gene expression [69-71]. For 
instance, ROS-mediated aberrant hyper-methylation can contribute 
to gene silencing, leading in certain cases, towards the progression 
to a malignant phenotype. This is the case of H2O2 in hepatocellular 
carcinoma, which induces hyper-methylation of the E-cadherin
gene promoter, causing E-cadherin down-regulation, thereby con-
tributing to epithelial-mesenchymal transition and promoting me-
tastasis [72]. ROS can also alter protein structure and function in 
several ways, by the modification of critical amino acid residues 
within the functional domain of proteins. By far, the best descrip-
tion of such modifications involves cysteine residues. The sulfhy-
dryl group of a single cysteine residue can be oxidized to form 
sulfenic, sulfinic, sulfonic, or S-glutathionylated derivatives. Such 
alterations may alter both the enzyme activity (if the critical cys-
teine is located within the catalytic domain) and the transcription 
factor-DNA binding activity (if the cysteine is located within the 
DNA binding motif), contributing to the non-genotoxic develop-
ment of carcinogenesis [73]. Therefore, by altering protein structure 
and function, ROS can act as secondary messengers in cell signal-
ing cascades, affecting the activation or the expression of transcrip-
tion factors and upstream kinases. For example, .OH and H2O2 can 
stimulate proliferation and survival in a wide variety of cell types, 
by deregulating the function of enzymes involved in the mitogen 
activated protein kinase (MAPK)- and phosphatidylinositol-3-OH 
kinase (PI3K)- dependent signaling pathways [74] (see 5. Prolifera-
tion and cancer). Then, these signaling cascades, leading to the 
activation of several redox-regulated transcription factors (e.g. acti-
vation protein-AP-1-, nuclear factor-kappa B-NF-kB- and hypoxia-
inducible factor-1-HIF-1-), up-regulate the expression of anti-
apoptotic and cell cycle genes, thereby ensuring cell survival and 
proliferation [74]. 
In conclusion, oxidative stress can cause oxidative cell damage, 
initiating and/or maintaining a tumorigenic cell phenotype. How-
ever, the “two-faced” functions of ROS must be taken into account, 
in that, by causing nondestructive or destructive oxidative cell dam-
age, ROS can act as pro-tumorigenic or as anti-tumorigenic chemi-
cal species, respectively.  
4.1. HTyr-Mediated Antioxidant Activity and Cancer 
HTyr is a well-established potent antioxidant, probably due to 
its orthodiphenolic structure and the high electron donating effect of 
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the second hydroxyl group [75]. Indeed, HTyr can protect cells 
from oxidative stress through two types of mechanisms: a direct 
antioxidant activity (with redox activity) and an indirect antioxidant 
activity (with or without redox activity). The data concerning these 
activities are reported in the paragraphs below.  
Several studies have shown that HTyr prevents ROS generation 
in normal and tumor cells, suggesting that it can also prevent oxida-
tive damage in both cell types, thereby preventing both initiation 
and promotion/progression of tumorigenesis. However, antioxidant 
effects occurring in an installed malignant disease, where the oxida-
tive status is altered, should be interpreted carefully. Indeed, the 
reduction of HTyr-mediated oxidative cell damage can cause both 
anti-tumorigenic (prevention of genetic mutation and proliferation 
signaling pathways) as well as pro-tumorigenic (promotion of pro-
liferation and/or inhibiting cell death) effects. In the latter case, 
HTyr might also inhibit the action of those chemotherapeutic agents 
that induce tumor cell death through oxidative cell damage [76].  
In contrast to the described antioxidant activity, in certain cases 
HTyr behaves as a “pro-oxidant” agent. In fact, depending on HTyr 
concentrations and cell culture media, HTyr can generate H2O2 in 
vitro [50, 54]. It was indicated that the main initiation step in the 
H2O2-producing activity is the auto-oxidation of HTyr by O2, lead-
ing to the formation of semiquinone O2- and 2H+ [54]. 
4.1.1. Direct Antioxidant Activity of HTyr and Cancer 
The direct antioxidant activity of HTyr was demonstrated in vi-
tro and in vivo. 
O’Dowd et al. [77] showed that HTyr (10-100 M) possessed a 
clear scavenging activity in human activated neutrophils in vitro, 
and indicated that this effect was exerted by scavenging H2O2 but 
not O2.-. Another in vitro study [78] showed that HTyr (50-100 M) 
reduced hemolysis and membrane lipoperoxidation of H2O2 pre-
treated human erythrocytes. The authors also reported that both 
methionine and leucine membranes transport were significantly 
reduced after H2O2 stimulation, suggesting that this could be one of 
the mechanisms underlying the protective role of HTyr on erythro-
cyte hemolysis. Furthermore, Fabiani et al. [79] showed that HTyr 
(1-10 M) prevented oxidative DNA damage in human normal 
blood mononuclear cells, and suggested that HTyr might efficiently 
prevent the initiation step of carcinogenesis in vivo, since the con-
centrations HTyr used could be easily reached with normal olive oil 
intake. It has been also shown [80] that HTyr (6.25-100 M) re-
duced basal and H2O2-induced ROS levels in the immortalized non-
tumorigenic MCF10A human breast epithelial cell line. All these 
results suggest that HTyr, inhibiting ROS production, can prevent 
oxidative DNA damage in normal and non-transformed cells in 
vitro, thereby preventing the initiation of a chain of reactions that 
transforms normal into cancer cells Fig. (3). This hypothesis is 
supported by an intervention study showing that the supplementa-
tion of postmenopausal women with high phenol extra-VOO caused 
decreased oxidative damage to lymphocyte DNA [81].  
Beyond these data obtained in non-transformed cells, evidence 
exists that HTyr can directly prevent oxidative DNA damage also in 
transformed cells in vitro. In a recent study performed in the human 
skin keratinocyte HaCaT cell line exposed to UVB, Guo et al. [82] 
reported that HTyr significantly decreased intracellular ROS forma-
tion and 8-hydroxydeoxyguanosine levels, reducing DNA strand 
breaks and p53 expression. These results strongly suggest that HTyr 
has a significantly protective effect against UVB-induced oxidative 
DNA damage. Moreover, it has been shown that HTyr, at potential 
physiological concentrations (1-100 M), protects other different 
cancer cell types, such as those derived from gut [83], blood [84], 
prostate [57], and breast [80], against oxidative damage induced by 
H2O2. This means, as discussed above, that HTyr might also protect 
tumor cells from the cytotoxic/proapoptotic action of some che-
motherapeutic agents. 
4.1.2. Indirect Antioxidant Activity of HTyr and Cancer 
Recent studies suggest that the anti-tumor effects mediated by 
HTyr are also derived from its indirect antioxidant activity, consist-
ing in the regulation of enzymes and signaling molecules implicated 
in oxidation. In fact, an important aspect of the biochemistry of 
phenolic antioxidants is their ability to form a variety of highly 
interesting arylating oxidation products. In particular, Cornwell et
al. [53] showed that HTyr, during its redox cycling, is converted to 
hydrophilic catechol quinone (hydroxytyrosol quinone, HTyrQ) 
electrophile. Thus, the hydrophilicity of HTyrQ allows it to react 
with available thiol nucleophilic groups (Michael addition reaction) 
present in enzymes and signaling molecules within the hydrophilic 
cell environment [85, 53]. 
It is of great interest that, HTyr (100 M) activates the nuclear 
factor-E2-related factor-2/antioxidant responsive element (Nrf2/ 
ARE) pathway in vitro, resulting in the increased transcription of 
both antioxidant enzymes (e.g. Cu/ZnSOD, MnSOD, peroxiredoxin 
3 and 5, thioredoxin-2) and phase II detoxifying enzymes (e.g. GSH 
S-transferase, NAD(P)H:quinone oxidoreductase 1 or GSH reduc-
tase) [86]. It is noteworthy, that the enhancement of phase II en-
zymes is a highly effective strategy for protection towards oxidant 
toxicity and carcinogenesis. Under basal conditions, Nrf2 is pre-
dominately bound into the cytoplasm to the Keap-1 protein, which 
is anchored to the actin cytoskeleton. When some inducers disrupt 
the Keap1-Nrf2 complex, Nrf2 is activated, migrates to the nucleus, 
heterodimerizes with a small MAF protein and binds to ARE in the 
upstream promoter region of many antioxidant genes. The activa-
tion of Nfr2 by HTyr might occur through the Michael addition 
reaction between HTyrQ and the cysteine thiol group in Keap-1, 
leading to Keap-1 dissociation from Nrf2 [85]. Moreover, by the 
activation of the Nfr2 and JNK-p62/SQSTM1 pathways, HTyr can 
induce the synthesis of GSH widely involved in tumorigenesis [87] 
Fig. (4). This hypothesis is supported by a very recent study in vivo, 
showing that a diet rich in olive oil phenols reduced oxidative stress 
in the heart of senescence-accelerated mouse-prone 8 mice by the 
induction of Nrf2-dependent gene expression [88].  
In conclusion, many studies focused on the toxicity and car-
cinogenicity induced by ROS generated by redox-active metals, 
such as iron. In this context, it is important to underlie the indirect 
antioxidant activity of HTyr mediated through its strong iron chelat-
ing capability, leading to the decrease of iron-derived ROS and of 
oxidative stress generation [60]. 
5. PROLIFERATION AND CANCER 
Physiological conditions, crucial mechanisms for maintaining 
tissue homeostasis are represented by the strict control of both cell 
proliferation and apoptosis under normal conditons. Shifting the 
balance from a state of equilibrium towards an increased prolifera-
tion can lead to the appearance of a neoplastic cell population. In 
fact, as above-mentioned, cancer hallmarks include insensitivity to 
growth-inhibitory signals, sustained growth-stimulatory signaling 
and evasion of apoptosis [52].  
Concerning the control of cell proliferation by growth-
inhibitory signals, two main mechanisms were proposed by Hana-
han and Weinberg [52]. The first mechanism is the prevention of 
normal cells to advance through the cell cycle G1 phase, maintain-
ing cells in a quiescent (G0) state. An example of such an anti-
growth signal is the soluble signaling factor transforming growth 
factor- (TGF), which blocks progression through the G1 phase of 
the cell cycle via the suppression of c-Myc and the activation of 
cyclin-dependent kinase (Cdk) inhibitors p15Ink4B and p21Cip1 [89]. 
Often, cancer cells acquire the inability to respond to inhibitory 
factors as a result of inactivating mutations, or downregulation of 
both the downstream signaling effectors and the receptors them-
selves [89]. The second mechanism involves the implementation of 
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differentiation programs, which induce an irreversible post-mitotic 
or terminally differentiated state. In certain cancer cells, the normal 
differentiation program is blocked and cells are maintained in a 
proliferative progenitor-like state. 
Concerning the control of cell proliferation by growth-
stimulatory signaling, two major signaling pathways, such as the 
Ras-MAPK/extracellular signal-regulated protein kinase (ERK) 
(Ras-MAPK/ERK) [90] and the PI3K/Akt [91] cascades, are fre-
quently involved in many human cancers. Deregulation of these 
pathways with promotion of self-sufficient cancer cell growth can 
occur by a variety of mechanisms, including mutations to both up-
stream and downstream components. Moreover, in the absence of 
MAPK-and PI3K-signaling-activating mutations, alternative mecha 
nisms may arise activating these pathways and conferring tumor 
cell growth autonomy. For example, COX-2-derived prostaglandin-
E2 (PGE2) (see 6. Inflammation and cancer) is able to signal via 
the Ras-MAPK/ERK and the PI3K/AKT-pathways to promote cell 
survival. Therefore, aberrant activation of the COX-2/PGE2 path-
way could enhance Ras-MAPK and/or PI3K/AKT signaling activa-
tion, promoting tumorigenesis [92].
Finally, evasion of apoptosis, the process of programmed cell 
death used by organisms to control cell number, is another critical 
Fig. (3). Direct antioxidant activity of HTyr and cancer. 
Fig. (4). Indirect antioxidant activity of HTyr and cancer. 
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mechanism by which cancer cells result in excessive cell survival 
and increased proliferation [93]. The ability of tumor cells to ac-
quire resistance to apoptosis can arise via a variety of mechanisms, 
the majority of which result in an impaired ability of the cell to 
engage the intrinsic cell death machinery, i.e. the mitochondrial 
apoptosis pathway. This pathway is governed by the ratio of pro-
apoptotic and anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein 
family members, which set a threshold for activation of the apop-
totic caspase cascade upstream of the mitochondria [94]. Moreover, 
it should be emphasized that the deregulation of the Ras-MAPK/ 
ERK and the PI3K/AKT signaling pathways, beyond the induction 
of cell growth autonomy, can also cause the prevention of apoptosis 
via the intrinsic cell death machinery [95, 96].
5.1. HTyr-Mediated Antiproliferative Activity and Cancer
The anticancer activity of HTyr has been studied as the result of 
its capability to inhibit cell proliferation by suppressing cell cycle 
progression and growth, and/or promoting apoptosis in several can-
cer cell lines in vitro. 
Della Ragione et al. [97] demonstrated that HTyr (50 and 100 
M) reduced proliferation by arresting cell cycle and inducing 
apoptosis in the human promyelocytic leukemia HL60 cell line, as 
well as in resting and activated peripheral blood lymphocytes. They 
also indicated that HTyr-mediated apoptosis depended on the re-
lease of cytochrome c, which activated the effector caspase-3. 
Then, the same authors [98] proposed that one of the possible 
mechanisms by which HT triggered apoptosis by cytochrome c 
release, could be the activation of the c-jun NH2-terminal kinase 
(JNK) transduction pathway, which induces the phosphorylation of 
the anti-apoptotic protein Bcl-2, inactivating it, thus causing cancer 
cell apoptosis. Partially according to these results, Fabiani et al. 
[98, 100] showed that HTyr (50 and 100 M) inhibited cell prolif-
eration of HL-60 cells, by blocking the cell cycle in the G1 phase, 
promoting apoptosis and inducing cell differentiation. The authors 
proposed the following HTyr-mediated mechanisms: 1) inhibition 
of Cdk; 2) induction of CdK inhibitors; 3) blockage of messengers 
involved in cell proliferation. Then, the same authors [101] reported 
that HTyr (100 M) decreases the expression of Cdk6 and in-
creased that of Cdk inhibitors p21WAF/Cip1 and p27Kip1 in the same 
cell type. They also proposed that HTyr-mediated apoptosis was 
due to both extracellular H2O2 production induced by the above-
mentioned HTyr-mediated pro-oxidant activity and the Michael 
addition reaction between HTyrQ and thiol groups in proteins, 
promoting endoplasmic reticulum (ER)-dependent stress with the 
consequent activation of pro-apoptotic signals [54, 102]. However, 
in contrast to Della Ragione et al. [95], no effect on apoptosis was 
observed on freshly isolated human lymphocytes and polymor-
phonuclear cells by Fabiani et al. [99]. This discrepancy could be 
due to the different apoptosis assays used by the two research 
groups.  
Recently, Guichard et al. [103] demonstrated that high (100-
400 M) HTyr doses inhibited the proliferation of human colon 
carcinoma HT-29 cells by inducing both cell cycle arrest (at phases 
S and G2/M) and apoptosis through JNK, Bcl-2, cytochrome c re-
lease, and caspase-3 activation. The authors indicated that HTyr 
specifically activated serine/threonine phosphatase PP2A, either 
directly or indirectly, by scavenging ROS (which are known to 
inhibit PP2A) or by inducing ER-dependent stress (which enhance 
the PERK signaling pathway). PP2A is known to play a key role in 
triggering various signaling pathways leading to apoptosis. These 
results agree, at least in part, with those of Della Ragione et al. [98], 
reporting an inhibition of the pro-survival extracellular signal-
regulated kinase (Erk) 1/2- and PI3K/Akt- NF-kB pathways, proba-
bly by PP2A activation. Notarincola et al. [104] observed anti-
proliferative effects on HT-29 and on another human colon cancer 
SW620 cell line by potentially physiological (10-100 M) HTyr 
doses. Moreover, Corona et al. [105] showed that HTyr (50-100 
M) exerted strong anti-proliferative effects against the Caco2 hu-
man colon adenocarcinoma cell line, by accumulation of cells in the 
cell cycle G2 phase and inhibition of ERK1/2 phosphorylation. 
According to previous results [103, 105], we showed that high 
(100-300 M) HTyr concentrations induced dose-dependent anti-
proliferative effects on HT-29 cells, by the induction of cell cycle 
arrest in the G2/M phase [106]. 
Recently, Han et al. [107] studied the MCF-7 breast cancer cell 
line and found that HTyr (324 M) inhibited cell proliferation by 
both cell cycle arrest in G0/G1 phase and apoptosis. Moreover, in 
the same cancer cell model, Bouallagui et al. [108] reported that the 
G0/G1 phase cell cycle arrest was associated with both a downregu-
lation of the expression of the peptidyl-prolyl cis-trans isomerase 
Pin-1, which in turn decreased cyclin D1 levels, and an up-
regulation of c-jun. In addition, Sirianni et al. [109] demonstrated 
that HTyr inhibited estradiol-induced MCF-7 cell proliferation by 
interfering with ERK1/2 activation. 
The only in vivo study was performed by Granados-Principal et
al. [110], showing that HTyr exerted anti-cancer effects in Spra-
gue–Dawley rats with experimental mammary tumors by inhibiting 
cell growth, through the alteration of several genes associated with 
cell proliferation, apoptosis and the Wnt signaling pathway. 
In contrast to these results showing the antiproliferative activity 
of HTyr, some authors have not detected any inhibition of cancer 
cell proliferation after HTyr treatment, also in the presence of 
HTyr-mediated reduction of oxidative cell damage [57, 80, 111]. 
These findings support the idea that, beyond the simple interference 
with radical processes, other mechanism(s) involving the specific 
interaction of HTyr with cellular target molecule(s) underlies HTyr-
mediated modulation of cell proliferation and apoptosis, and that 
further studies are necessary to elucidate the signaling events tar-
geted by HTyr in cancer cell proliferation.  
In conclusion, these data indicate that HTyr can mediate anti-
proliferative activity on cancer cells by potentially targeting spe-
cific oncogenic pathways. Moreover, most that is currently known 
comes from in vitro studies. In vivo investigations are needed to 
demonstrate the HTyr capability of inhibiting tumor cell prolifera-
tion. 
6. INFLAMMATION AND CANCER 
The immune system is considered as a “double-edged sword” in 
cancer, in that it protects the host destroying tumor cells (i.e. im-
muno-surveillance), and yet, paradoxically, it promotes and sustains 
cancer (the result of a process known as cancer immuno-editing) 
[112, 113]. Hence, the effectiveness of immuno-surveillance and 
response to therapy depends on the balance between anti- and pro-
tumorigenic immunity [114].
Inflammation is an important part of the innate immune re-
sponse and a salutary response to various insults. However, there is 
a growing body of evidence that inflammation is a critical compo-
nent of protumorigenic immunity. Chronic inflammation associated 
with infections, autoimmunity, environmental and dietary expo-
sures represents a promoter of tumor development, and several 
types of cancers (lung, colorectal, gastric, pancreatic, hepatocellu-
lar, cervical, ovarian, skin, bladder, gall bladder cancers) are asso-
ciated with chronic inflammatory diseases [115, 116]. In addition, 
inflammation can also follow tumor development. In fact, most, if 
not all, solid malignancies trigger an intrinsic inflammatory re-
sponse that builds up a protumorigenic microenvironment, promot-
ing cancer progression [113, 116]. Therefore, inflammation can 
contribute to all the carcinogenic steps, such as cancer initiation (by 
innate immune cell-mediated oxidative cell damage; see 4. Oxida-
tion and cancer), promotion (by inducing cell proliferation), and 
progression (by promoting neo-angiogenesis and metastasis). 
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Moreover, inflammation can cause local immunosuppression, po-
larizing immunity towards a tumor-promoting phenotype [115, 
116].  
Recent research has highlighted an important role for mono-
cytes/macrophages in the pro-tumor inflammatory reactions. Mono-
cyte/macrophages are an exceptionally heterogeneous population of 
cells (e.g. M-1 and M-2 polarizing macrophages, dendritic cells-DC 
and myeloid-derived suppressor cells-MDSC), which function in 
distinct differentiation forms and adopt different activation states 
and functions in response to a changing microenvironment [117-
119]. Indeed, macrophages can be central orchestrators of chronic 
inflammatory diseases, predisposing to cancer initiation. Moreover, 
macrophages, together with T cells, are the most frequently found 
immune cells within the microenvironment of established tumors 
that are not epidemiologically related to chronic inflammation [120, 
121], and high tumor-associated macrophages content generally 
correlates with poor prognosis [117]. Tumor-associated macro-
phages display several pro-tumorigenic functions, promoting tumor 
survival, tumor growth, neo-angiogenesis, invasion and metastasis, 
as well as, suppressing the anti-tumor immune response. Therefore, 
monocytes/macrophages can drive all the phases of carcinogenesis, 
from cancer initiation and immuno-editing to cancer progression 
and metastasization [118-121]. Once arrived in the inflamed tissue, 
macrophages produce protumorigenic inflammatory mediators and 
immunosuppressive factors, through the activation of their inflam-
matory signaling pathways [119]. The transcriptional factors NF-kB 
and HIF-1 have been identified as master regulators of macrophage 
transcriptional programs and, inducing the expression of genes 
encoding factors affecting malignant cells and tumor stroma, are 
central regulators of tumorigenesis [76, 122]. The protumorigenic 
mediators produced by macrophages include: a) growth factors 
(GF) (EGF, PDGF, FGF, HGF), survival signals such as pro-
inflammatory cytokines (tumor necrosis factor-TNF-, interleukin 
(IL)-1, IL-6), L-arginine derived polyamines, and PGE2; b) angio-
genic factors such as vascular endothelial growth factor (VEGF), 
chemokines, cytokines (GM-CSF, TGF- and -, TNF, IL-1, IL-6, 
IL-8), and PGE2; c) factors promoting invasion and metastasis such 
as chemokines, cytokines (TNF, IL-1) and enzymes (matrix metal-
loproteinases-MMP-9, urokinase-type plasminogen activator-uPA); 
d) immunosuppressive factors such as cytokines (e.g. IL-10, TGF-
), PGE2, indoleamine-2,3-dioxygenase (IDO), arginase, O2.-, and 
peroxynitrite, which inhibit innate and adaptive anti-tumor immune 
responses [116, 120, 123].  
6.1. In Vitro HTyr-Mediated Anti-Inflammatory Activity and 
Cancer 
The anti-inflammatory activity of HTyr has been studied as the 
result of its capability of inhibiting the protumorigenic inflamma 
tory responses mediated by murine and human monocytes and 
macrophages in vitro.  
Richard et al. [124] showed that the treatment of LPS-activated 
RAW264.7 murine macrophages with HTyr (25 M) reduced the 
production of several pro-inflammatory mediators, including cyto-
kines (IL-12, IL-6, IL-1, TNF), chemokines (CXCL10/IP-10, 
CCL2/MCP1, MIP-1) and enzymes (MMP-9, PGE2 synthase, and 
inducible nitric oxide synthase-iNOS-). Accordingly, Giner et al. 
[125] reported the inhibition of cytokine (IL-1, IL-6, and TNF) 
production by LPS-stimulated peritoneal macrophages treated with 
HTyr (100 M). A similar anti-inflammatory activity was also 
shown in humans, where HTyr (50-100 M) remarkably inhibited, 
in a dose-dependent manner, TNF production and secretion by 
LPS-stimulated THP-1 monocytes [126]. Altogether, these results 
show that HTyr can inhibit macrophages/monocytes production of 
several inflammatory cytokines and enzymes that play a central role 
in tumorigenesis. In particular, TNF, acting on tumor and stromal 
cells, is a major mediator of cancer-related inflammation [127]. In 
fact, TNF can induce genetic changes and NF-kB activation in 
tumor cells, upregulating anti-apoptotic and cell cycle gene expres-
sion, thereby ensuring cell survival and proliferation. In addition, 
TNF, by NF-kB activation, upregulates COX-2 expression in tu-
mor cells, and promotes tumor angiogenesis and metastasis. Finally, 
TNF suppresses adaptive and innate immunity. Because of these 
several important tumorigenic actions, TNF is now considered a 
therapeutic target in cancer treatment, and TNF antagonists have 
been shown to exert therapeutic activity in Phase I and II clinical 
cancer trials. Therefore, in the light of these considerations, we 
might assume that HTyr, by inhibiting TNF induction by macro-
phages, might play a key anti-tumor inflammatory action. 
Maiuri et al. [128] demonstrated that HTyr (100-200 M) 
down-regulated, in a dose-dependent manner, the synthesis of 
PGE2 in LPS-stimulated J774 murine macrophages. Accordingly, 
Richard et al. [124] showed that HTyr inhibited PGE2 production 
in LPS-stimulated RAW264.7 murine macrophages. Maiuri et al. 
[128] also reported that the PGE2 synthesis down-regulation paral-
leled the inhibition of COX-2 gene expression in activated J774 
macrophages. According to these results, Zhang et al. [129] showed 
that HTyr (50-100 M) suppressed COX-2 expression in LPS-
stimulated THP-1 monocytes. Since COX-2 is the enzyme deputed 
to PGE2 generation from arachidonic acid, these data show that 
HTyr blocks COX-2 production by macrophages, thus inhibiting 
the synthesis of PGE2. The fact that HTyr inhibits the COX-2-
PGE2 pathway in macrophages is very important, since PGE2 ex-
erts pleiotropic effects on tumors influencing several aspects of 
tumorigenesis [92]. In fact, PGE2 promotes proliferation/survival 
(see 5. Proliferation and cancer) and metastasis in tumor cells, 
orchestrates the process of neo-angiogenesis in several ways, and 
act as an immunosuppressive factor. Altogether these considera-
tions suggest that HTyr, inhibiting the COX-2-PGE2 pathway in 
macrophages, might play a central role in the suppression of tu-
morigenesis.  
Interestingly, most of the authors cited above [124-126, 128] 
also showed that the HTyr-mediated inhibitory production of pro-
tumorigenic inflammatory factors by activated macrophages arises 
from the prevention of the activation of some transcriptional fac-
tors, including NF-kB. Importantly, NF-KB in macrophages regu-
lates the expression of a large variety of genes encoding for immun-
oregulatory mediators (e.g. inflammatory cytokines and COX-2) 
implicated in carcinogenesis [74, 92]. Moreover, NF-kB inhibition 
by HTyr has been observed at physiological HTyr concentrations 
[124-126, 128]. The mechanism by which HTyr prevents the activa-
tion of transcription factors is not completely clear. Although most 
studies suggest that the anti-inflammatory effects of HTyr are 
mostly attributable to its antioxidant properties, as already men-
tioned in this review (see 4. Oxidation and cancer; 5. Proliferation 
and cancer), HTyr can also directly target specific biochemical and 
signaling oncogenic pathways [47-49, 53]. One mechanism pro-
posed for this activity involves HTyrQ from HTyr metabolism, 
which reacts with available thiol nucleophilic groups (Michael ad-
dition reaction) present in signaling molecules within the hydro-
philic cell environment [53]. The fact that NF-kB contains a critical 
cysteine residue for its DNA binding capability, that can be inhib-
ited by specific arylating agents, makes NF-kB a plausible and in-
terest target. The capability of HTyr of bringing about arylating 
adducts in the residues of NF-kB cysteine, hampers the bonding of 
this transcription factor with DNA, thus inhibiting its activity [53] 
Fig. (5). It should be noted that, since several recent studies have 
been devoted to the development of new molecules that are inhibi-
tors of the enzymatic activity of either iNOS or COX-2, the preven-
tion by HTyr of the expression of the gene coding for these en-
zymes, through NF-kB inhibition, might represent an alternative 
molecular approach. 
In conclusion, these data report that HTyr may act as a potent 
anti-inflammatory agent in vitro, by inhibiting pro-tumorigenic 
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inflammatory responses mediated by the activation of mono-
cytes/macrophage. In particular, the inhibition of the NF-kB signal-
ing pathways may play a central role in HTyr-mediated anti-
inflammatory activity.
6.2. In Vivo HTyr-Mediated Anti-Inflammatory Activity and 
Cancer 
The in vivo anti-inflammatory effect of HTyr has been studied 
in different experimental animal models of inflammation. Bitler et 
al. [11] found that olive vegetation water highly enriched in HTyr 
(125 mg/mouse; 500 mg/kg) reduced serum TNF levels by 95% in 
LPS-treated mice. Gong et al. [130] studied rats with acute inflam-
mation induced by intravenous injection of carrageenan at 2% 
(w/v). The rodents received different dosages (100, 250, and 500 
mg/kg of body weight) by gavage of a preparation in which the 
main ingredients were HTyr (22%), polyphenol (4%), saccharide 
(67%), lipid (2%), ignition residue (4%), and moisture (1%). This 
preparation, called HT-20, significantly inhibited the acute inflam-
mation and lowered tissue IL-1 and TNF levels. More recently,
Sánchez-Fidalgo et al. [131] reported that HTyr -enriched extra-
VOO attenuated chronic dextran sulfate sodium (DSS)-induced 
colitis in mice and decreased COX-2, iNOS via downregulation of 
p38MAPK. Accordingly, Giner et al. [125] found that oleuropein 
ameliorates acute DSS-colitis in mice while reducing TNF, IL-1
and IL-6 production, iNOS, COX-2 and MMP-9 expression, and 
NF-kB activation in colon tissue.  
In conclusion, animal experiments support in vivo most of the 
evidence obtained in vitro, in that ingested HTyr exerts anti-
inflammatory activity, and this activity is very likely mediated by 
inhibiting macrophage production of protumorigenic inflammatory 
mediators, principally through the inhibition of NF-kB activation. 
However, it should be emphasized, that most of the experiments 
have been performed with mixture of olive phenols, in which HTyr 
was the most active ingredient but not the exclusive one. Synergy 
with other olive phenols cannot, at present, be excluded.  
CONCLUSIONS 
Epidemiological studies have shown an association between di-
ets rich in olive oil phenols and lower cancer mortality. Current 
knowledge indicates HTyr as one of the major active phenolic 
components in olive oil, potentially capable of counteracting cancer 
hallmarks. In the last few years, several synthetic procedures have 
been optimized to obtain pure HTyr, so that the investigation of its 
biological activities could readily occur. The studies reported in this 
review indicate HTyr as a powerful antioxidant, as well as antipro-
liferative and anti-inflammatory agent, suggesting promising cancer 
chemopreventive and chemotherapeutic properties of HTyr. Efforts 
have been made nowadays to elucidate cellular and molecular tar-
gets of HTyr, and, notably, HTyr results as a potential multifunc-
tional compound, capable of targeting multiple signaling oncogenic 
and inflammatory pathways. However, further studies in this direc-
Fig. (5). Anti-inflammatory activity of HTyr and cancer. 
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tion are still needed to clarify these activities. Moreover, as dis-
cussed here, most of the current knowledge comes from studies 
performed in vitro. Although these investigations largely contrib-
utes to a better understanding of the potential biological activities of 
HTyr, evidence obtained in vitro do not necessarily correspond to 
those found in vivo, especially when the concentrations of HTyr 
used in some experiments seems higher than those potentially 
achievable in vivo. Hence, preclinical research is needed to confirm 
HTyr-mediated anti-cancer activities and effectively utilize this 
compound in cancer prevention and treatment. 
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